0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Use of Growth Hormone and Insulin-Like Growth Factor I in Catabolism That Is Induced by Negative Energy Balance

      Hormone Research in Paediatrics

      S. Karger AG

      Catabolism, Anabolism, Somatomedin C, Nitrogen balance

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Both GH and insulin-like growth factor I (IGF-I) have been shown to promote anabolism in human volunteers that are made catabolic by caloric restriction. We have used caloric restriction as a model of controlled catabolism to test the efficacy of these agents in reversing negative nitrogen balance. Six normal volunteers underwent caloric restriction for 2-week intervals. This restriction induced negative nitrogen balance (e.g. -239 mmol/day). During the second week either IGF-I (16 μg/kg h) was administered by intravenous infusion for 16 h, or GH (0.05 mg/kg) was given subcutaneously daily. GH alone improved nitrogen balance by 180 mmol/day, and IGF-I improved it by 175 mmol. The two hormones had opposite effects on carbohydrate metabolism. Mean blood glucose rose approximately 26% with GH whereas it fell 37% with IGF-I and the subjects had frequent hypoglycemic episodes during the infusion. Minimal complications were observed during the 6 days of IGF-I infusion and consisted primarily of edema and jaw pain. It appeared that IGF-I was as efficacious as GH in reversing the negative nitrogen balance induced by caloric restriction and that hypoglycemia induced by IGF-I was the major limiting factor. In a second study 7 volunteers underwent the identical caloric restriction. In contrast to the first study one treatment group received the combination of GH plus IGF-I given in exactly the same doses as in the first study. A second group received IGF-I alone. The combination of GH/IGF-I was much more potent in improving nitrogen balance. Specifically the subjects improved nitrogen balance by 260 mmol versus 170 mmol with IGF-I alone. Most of the nitrogen appeared to have entered the muscle compartment since urinary potassium excretion was also markedly reduced with GH/IGF-I. The effects on carbohydrate metabolism were divergent. The subjects who received combined treatment maintained normal glucose homeostasis and normal insulin and C peptide concentrations whereas the subjects who received IGF-I had suppression of C peptide and hypoglycemia. The combination of GH/IGF-I obviates several problems that occur with either GH or IGF-I alone. Carbohydrate metabolism is maintained at near-normal levels, and episodes of hypoglycemia are attenuated particularly if GH is administered prior to administering IGF-I. The combination is much more potent in terms of improving nitrogen balance suggesting that it will be a better therapy for subjects who have severe catabolic illnesses.

          Related collections

          Author and article information

          Journal
          HRE
          Horm Res Paediatr
          10.1159/issn.1663-2818
          Hormone Research in Paediatrics
          S. Karger AG
          978-3-8055-5924-9
          978-3-318-01776-2
          1663-2818
          1663-2826
          1993
          1993
          05 December 2008
          : 40
          : 1-3
          : 62-67
          Affiliations
          Division of Endocrinology, Department of Medicine, UNC School of Medicine, Chapel Hill, N.C., USA
          Article
          183769 Horm Res 1993;40:62–67
          10.1159/000183769
          8300052
          © 1993 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 6
          Categories
          Session II: Pathophysiology of GH

          Comments

          Comment on this article